Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 25091 - ACCELERO: Ph3 Study to evaluate PF-08046054 vs Docetaxel in PD-L1+ NSCLC
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER
Disease Types: Lung - Non-Small Cell Lung
Available at: Arlington Heights, Chicago, Niles